Intellia Earnings: Gene Editing Pipeline Progresses; Shares Attractive for Risk-Tolerant Investors

No-moat Intellia Therapeutics’ gene editing pipeline is continuing to make progress as it dosed the first patient in its global phase 3 study evaluating NTLA-2002 in hereditary angioedema. Management has made the strategic decision to prioritize late-stage programs—NTLA-2002 and Nex-z (formerly NTLA-2001 in ATTR amyloidosis) to focus on near-term value creation. As a result, management discontinued NTLA-3001 (a gene editing treatment for lung disease) and it is reducing its workforce by approximately 27% in 2025. Intellia expects to incur charges of approximately $8 million for severance and other employee termination-related costs in the first quarter of 2025.